The research, led by Wenqing Hu, Qian Chen, Shuyang Zhu and colleagues, mapped these chromatin hubs at high resolution and discovered that within days of exposure to a chronic viral infection, activated CD8+ T cells begin assembling distinct three-dimensional DNA structures that lock in their future identity long before the cells display the surface markers traditionally used to distinguish exhausted T cell subsets. The team showed that early exhausted CD8+ T cells diverge into two well-defined populations: exhaustion-prone effector T cells, characterized by the loss of the transcription factor Tcf1, low expression of the surface marker Slamf6 and high expression of the inhibitory receptor Tim3, and precursor exhausted T cells, or Tpex cells, which maintain Tcf1 expression, high Slamf6 and low Tim3 while retaining the capacity for self-renewal. The choice between these fates, the researchers found, is imprinted by the formation of self-associating chromatin hubs—clusters of genomic regions that physically come together within the nucleus to coordinate gene expression programs specific to each lineage.

Chromatin, the complex of DNA and proteins that packages the genome, is far from a passive spool. Its spatial organization brings distant regulatory elements into contact with the genes they control, and these contacts can determine whether a gene is switched on or silenced. By mapping which genomic regions self-associate in early exhausted T cells, the researchers observed that hub assembly coincided precisely with the induction of effector genes in one subset and stemness genes in the other. In other words, the physical folding of the genome was not a consequence of fate commitment but appeared to be an active mechanism driving it. The discovery reframes T cell exhaustion not simply as a gradual epigenetic erosion under chronic antigen stimulation, but as an architecturally orchestrated lineage decision executed with remarkable speed and precision.

At the heart of this regulatory network sit two members of the Id protein family, Id2 and Id3. These transcriptional cofactors are best known as inhibitors of DNA binding: they lack DNA-binding domains of their own and instead function by sequestering E proteins, a class of transcription factors that would otherwise activate a broad suite of genes. The new study identifies Id2 and Id3 as key determinants of exhausted CD8+ T cell fate, but—and this is where the biology becomes genuinely surprising—the two proteins push developing T cells in opposite directions. Id2 promoted the exhaustion-prone effector fate, while Id3 was required to establish and maintain the precursor exhausted fate. Deleting or perturbing either factor redirected cells toward the alternative pathway, demonstrating that the balance between Id2 and Id3 acts as a molecular switch governing the fork in the road.

The mechanistic details of how each Id protein exerts its influence reveal a sophisticated layer of gene regulation. Id2 drove specification of the exhaustion-prone effector population by activating a program of effector genes—the machinery of cytotoxicity and inflammatory cytokine production—while simultaneously suppressing genes associated with exhaustion checkpoints and stemness. This makes intuitive sense for a cell designed to fight hard and die fast: Id2 essentially suppresses the brakes while flooring the accelerator. Id3, by contrast, did the opposite. It repressed effector genes and upregulated expression of the interleukin-7 receptor alpha chain and the aryl hydrocarbon receptor, AhR, two molecules closely associated with cell survival, environmental sensing and long-term maintenance. Through this program, Id3 sustained the pool of Tpex cells, preserving the renewable reservoir from which exhausted immune responses are continually replenished.

Beneath these opposing transcriptional outputs lies an even deeper mechanistic distinction: the two Id proteins engage different partners to reshape the chromatin accessibility landscape of early exhausted T cells. Id2 worked in concert with the transcription factor Runx3 alongside E proteins, promoting opening of effector gene loci and closure of stemness-associated regions. Id3 partnered with Tcf1, the master transcription factor of the stem-like state, again in combination with E proteins, to maintain accessibility at genes required for self-renewal while keeping effector programs inaccessible. The finding that Id proteins—which do not bind DNA directly—can sculpt chromatin accessibility through these lineage-specific partnerships explains how a single family of cofactors can produce two radically different epigenetic outcomes depending on which transcription factor it recruits.

The implications for understanding chronic disease are substantial. Exhausted T cells are the defining immunological feature of persistent viral infections such as HIV, hepatitis B and hepatitis C, and they dominate the tumor microenvironment in most solid cancers. The Tpex population has attracted intense interest because it serves as the target cell population for immune checkpoint blockade: when drugs such as anti-PD-1 antibodies reinvigorate exhausted T cells, they do so primarily by expanding Tpex cells and their progeny. A deeper understanding of how Tpex cells are generated and maintained at the chromatin level could therefore inform strategies to make immunotherapies more effective, durable and applicable to patients who currently do not respond.

The study also carries a conceptual lesson that extends beyond exhausted T cells. Lineage decisions in many biological systems—from embryonic stem cells differentiating into tissue precursors to hematopoietic stem cells committing to blood lineages—have long been studied through the lens of transcription factor binding and histone modifications. The demonstration that self-associating chromatin hubs form within days of fate divergence, and that their assembly coincides with the earliest gene expression changes, suggests that three-dimensional genome architecture may be a general and underappreciated mechanism for specifying and stabilizing cell identity. Once a cell assembles the hub structure appropriate to its fate, that architecture may actively reinforce the transcriptional program, ensuring what the authors describe as lineage stability—the resistance of a committed cell to drifting back toward an alternative identity.

The technical achievement underlying these insights should not be overlooked. Identifying subset-specific chromatin hubs in rare, short-lived populations of T cells during the earliest days of an immune response requires coupling sophisticated genomic assays that detect physical interactions between genomic regions with flow cytometric sorting strategies capable of isolating Tcf1−Slamf6loTim3hi and Tcf1+Slamf6hiTim3lo cells from infected tissue. By integrating these maps with chromatin accessibility profiling and transcription factor perturbation experiments, the team was able to connect architecture, accessibility and gene expression into a coherent causal model. The identification of Id2 and Id3 as the pivotal regulators emerged precisely because the hub maps pointed to the regulatory elements whose activity differed between the subsets, narrowing the search among hundreds of candidate factors.

For the field of T cell immunology, the study resolves a long-standing puzzle about the timing of exhaustion. Researchers have debated whether exhaustion is a linear differentiation process, in which cells progressively lose function under continuous antigen stimulation, or whether distinct fates are specified early and then maintained. The new data strongly support the latter view: fate is imprinted almost immediately, at the level of chromatin architecture, and the Id proteins act at this early node to channel cells irreversibly toward effector exhaustion or precursor self-renewal. This early specification helps explain why chronically stimulated T cells rarely revert to full functionality and why therapeutic reinvigoration depends so heavily on preserving and expanding the precursor compartment rather than attempting to reverse terminal exhaustion.

Looking forward, the findings open several avenues for translational exploration. Manipulating Id2 and Id3 activity—or the chromatin hub structures they organize—could potentially shift the balance between effector and precursor fates in clinically desirable directions: tilting tumor-infiltrating T cells toward more durable precursor-like states that can sustain long-term antitumor responses, or enhancing effector commitment in contexts such as chronic infection where immediate cytotoxic pressure is needed. The involvement of AhR, a receptor sensitive to dietary and microbial metabolites, adds an intriguing environmental dimension to fate regulation that may connect T cell exhaustion to metabolism and the microbiome. While such applications remain speculative, the identification of a chromatin architectural switch at the root of T cell fate provides a concrete molecular target where previously there was only phenomenology.

What emerges from this work is a vivid picture of the genome as an actively organized structure whose physical conformation participates directly in cell fate decisions. Within days of encountering a chronic virus, a CD8+ T cell folds specific regions of its DNA into hubs, recruits Id2 or Id3 together with Runx3 or Tcf1, opens the genes appropriate to its chosen destiny and closes the rest. Effector cells seal their short, fiery fate; precursor cells lock in their patient, renewable one. The immune system, it turns out, does not merely read the genome—it rebuilds it in three dimensions to write the decision down.

Raquel Espin Palazon and colleagues at Iowa State University investigated why this differentiation breakdown occurs. Their work centers on progranulin, a widely expressed protein known for roles in cell growth, tissue repair, and inflammation, but whose myeloid-specific function was unclear.

The team leveraged a challenge: in mammals, progranulin is produced from a single gene throughout many tissues, making it difficult to isolate effects on blood-cell development. To overcome this, they used zebrafish, which contain two progranulin genes, enabling more precise, blood-related perturbations.

Earlier zebrafish work from the same group indicated that one blood-expressed progranulin gene is required for myeloid progenitors to mature into macrophages and neutrophils. Building on that foundation, the researchers attempted to stimulate human leukemia cells with progranulin to see whether differentiation could be rescued, initially without success.

They then returned to zebrafish lacking the blood-cell progranulin component and mapped the downstream consequences. A key defect emerged in the JAK2/STAT3 signaling axis, a pathway that transduces extracellular cues to nuclear gene-expression programs.

Crucially, both progranulin and active JAK2/STAT3 were required for definitive myeloid fate decisions. In leukemia contexts where JAK2/STAT3 signaling is hyperactivated, adding progranulin restored maturation capacity, pushing cells to complete a differentiation trajectory that culminates in their loss through normal lifecycle progression.

Beyond leukemia, the study distinguishes embryonic macrophage populations with different molecular dependencies. One population depends on both progranulin and JAK2/STAT3, while another does not, suggesting that macrophage “identity” is partially encoded by signaling logic during development.

The findings point to a therapeutic strategy: combine pathway activation states with targeted differentiation cues rather than relying solely on cytotoxic approaches. If translated, interventions that modulate progranulin-dependent signaling could steer malignant progenitors toward terminal maturation.

Researchers caution that clinical development will take years, including validation of safety, delivery, and whether pathway states in patients predict responsiveness. Still, the work demonstrates how in vivo models can reveal synergistic requirements that isolated cell systems can miss.

Subject of Research: Myeloid leukemia
Article Title: Synergistic cooperation between progranulin and Jak2/Stat3 signaling determines definitive myeloid cell fate
News Publication Date: 10-Jun-2026
Web References: http://dx.doi.org/10.1016/j.celrep.2026.117477
References: Cell Reports (10.1016/j.celrep.2026.117477)
Image Credits: Raquel Espin Palazon/Iowa State University

Keywords: leukemia; myeloid differentiation; progranulin; JAK2/STAT3; zebrafish; macrophages; signaling synergy; immune cell fate

Clear cell renal cell carcinoma accounts for approximately 70-80% of all renal cancers and poses substantial challenges in treatment due to its heterogeneous nature and variable responses to immunotherapy. The quest for reliable prognostic biomarkers is vital to tailor therapeutic strategies and predict patient prognosis more accurately. The current work leverages state-of-the-art bioinformatics tools and multiple large-scale cancer databases, including The Cancer Genome Atlas (TCGA) and the Tumor Immune Estimation Resource (TIMER), to dissect the expression patterns and immune correlates of ZNF683 across a broad patient cohort.

ZNF683, also known as Hobit, is a zinc finger transcription factor implicated in regulating immune cell differentiation and function. Despite previous studies highlighting its aberrant expression in various malignancies, its specific role in renal cancer, and more importantly in ccRCC, has remained elusive. By integrating multi-omics datasets, the researchers performed a comprehensive analysis revealing that ZNF683 mRNA levels are markedly elevated in ccRCC tumor tissues relative to matched normal counterparts. This aberrant upregulation was further confirmed at the protein level via data from the Human Protein Atlas (HPA), which demonstrated robust ZNF683 staining predominantly within renal tumor cells.

Crucially, the study delved into the intricate relationship between ZNF683 expression and the tumor immune microenvironment. Using advanced immune cell deconvolution algorithms such as CIBERSORT, the analysis identified a significant positive correlation between ZNF683 levels and the infiltration of several key immune subsets, including CD8+ cytotoxic T lymphocytes, regulatory T cells (Tregs), B cells, natural killer (NK) cells, macrophages, and dendritic cells. This finding suggests that ZNF683 may play a critical role in orchestrating the immune landscape of ccRCC tumors, potentially influencing immunosurveillance and tumor immune evasion mechanisms.

The implications of these immune associations extend into immunotherapeutic responsiveness. The researchers observed that elevated ZNF683 expression correlates not only with increased infiltration of immune cells but also with the modulation of essential immune checkpoints, notably PD-1 (Programmed cell death protein 1). Given PD-1’s central role in immune inhibition and its targeting by checkpoint blockade therapies, this link posits ZNF683 as a possible modulator of immunotherapy efficacy in ccRCC. Interestingly, patients with high ZNF683 expression exhibited reduced sensitivity to current immunotherapeutic regimens, highlighting the need to consider ZNF683 status during therapeutic decision-making.

Methodologically, the study stands out for its multi-faceted approach. Beyond mining publicly accessible transcriptomic and clinical data, the authors conducted quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) experiments on renal cancer tissue samples to validate transcriptional upregulation of ZNF683. This integration of in silico and experimental data strengthens the robustness of their findings and emphasizes the translational potential of ZNF683 as a biomarker.

Diving deeper into survival analysis, Kaplan-Meier plotter and other prognostic tools demonstrated that elevated ZNF683 expression portends worse clinical outcomes for ccRCC patients. This prognostic value remained significant even after adjusting for conventional clinicopathological variables, underscoring ZNF683’s independent predictive capacity. Such data advocate for incorporating ZNF683 into prognostic modeling to refine risk stratification and personalized patient management in renal cancer.

The study’s findings also open avenues to explore ZNF683 as a therapeutic target. Given its apparent centrality in sculpting the tumor immune milieu and influencing immune checkpoint pathways, modulating ZNF683 function could enhance immunotherapeutic responses or overcome resistance mechanisms. Still, the molecular mechanisms through which ZNF683 exerts these immunomodulatory effects warrant further experimental elucidation.

Moreover, this research contributes to a growing body of evidence highlighting the complexity of the tumor immune microenvironment in renal cancer. The multifaceted immune infiltration pattern linked with ZNF683 underscores the dynamic interactions between tumor cells and various immune populations, including effector and suppressive cell types, that govern tumor progression and therapeutic outcomes.

Importantly, this study demonstrates the power of leveraging multiple bioinformatics platforms—such as TIMER, GEPIA, TISIDB, and the ESTIMATE algorithm—to perform comprehensive immune-related analyses. This integrative strategy enhances the reliability and scope of findings, facilitating precision oncology approaches aimed at stratifying patients and tailoring immunotherapies.

As the landscape of ccRCC treatment evolves with the advent of immune checkpoint inhibitors and combination therapies, identifying biomarkers like ZNF683 that inform immune infiltration and predict therapeutic sensitivity becomes paramount. By spotlighting ZNF683, this research paves the way for future clinical investigations that could incorporate its assessment into biomarker panels guiding therapy selection.

In conclusion, the multi-omics exploration of ZNF683 in ccRCC propels our understanding of kidney cancer immunobiology forward. The protein’s marked overexpression in tumors, its tight correlation with diverse tumor-infiltrating immune cells, and its association with diminished immunotherapeutic response collectively assert ZNF683 as a critical player in ccRCC pathogenesis. Future studies directed at unraveling its mechanistic roles and therapeutic targeting potential may hold promise for improving outcomes in patients battling this formidable cancer.

The academic and clinical communities stand to benefit greatly from these revelations, which not only enhance prognostic accuracy but also underscore the intricate crosstalk between transcription factors and immune regulation in the tumor microenvironment. As immunotherapy continues to reshape oncology paradigms, integrating biomarkers like ZNF683 will be essential to maximizing patient benefit and overcoming resistance hurdles in ccRCC.

Such pioneering work exemplifies the intersection of big data, molecular biology, and immuno-oncology, demonstrating how transcriptomic signatures can illuminate new biological insights and catalyze breakthroughs in cancer management. ZNF683 now emerges from obscurity as a promising beacon guiding personalized medicine efforts in renal cancer, warranting further translational and clinical validation.

Subject of Research: Zinc Finger Protein 683 (ZNF683) as a prognostic biomarker linked to immune infiltration in clear cell renal cell carcinoma (ccRCC).

Article Title: Multi-omics analysis of zinc finger protein 683 as a prognostic biomarker for immune infiltration in clear cell renal cell carcinoma.

Article References:
Guo, Y., Wang, Y., Ding, G. et al. Multi-omics analysis of zinc finger protein 683 as a prognostic biomarker for immune infiltration in clear cell renal cell carcinoma.
BMC Cancer 25, 1236 (2025). https://doi.org/10.1186/s12885-025-14643-6

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14643-6